Imipenem Prophylaxis in Patients With Acute Pancreatitis
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, randomized, placebo-controlled, double-blind clinical
trial that aims to investigate the beneficial and harmful effects of prophylactic use of
imipenem in patients with predicted severe acute pancreatitis. All patients with first attack
of acute pancreatitis, an onset of disease less than 72h before admission, and an APACHE II
score ≥ 8 calculated within the first 24h from admission will be enrolled.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Rijeka
Collaborator:
University of Rijeka
Treatments:
Cilastatin Cilastatin, Imipenem Drug Combination Imipenem